Biodexa Announces 1-for-8 Reverse ADS Split Effective October 26
Summary
Biodexa Pharmaceuticals announced a 1-for-8 reverse ADS split effective October 26, 2026, changing the ADS ratio from 1:50 to 1:400 ordinary shares to lift the ADS price above Nasdaq's $1.00 minimum bid requirement.
Updates
· SEC 424B3 — The 424B3 prospectus supplement incorporates the October 8, 2026 Form 6-K announcing the 1-for-8 reverse ADS split effective October 26, 2026.
Key Events · Corporate Governance and Compliance · BDRX
-
1-for-8 Reverse ADS Split Announced
Biodexa will change its ADS ratio from 1 ADS representing 50 ordinary shares to 1 ADS representing 400 ordinary shares, effective on or about October 26, 2026. ADS holders must surrender 8 old ADSs to receive 1 new ADS.
-
Nasdaq Compliance Motivation
The ADS price closed at $0.3832 on October 12, 2026, below the $1.00 Nasdaq minimum bid requirement. The reverse split is intended to raise the ADS price above this threshold.
-
Mandatory Exchange Process
JPMorgan Chase Bank, N.A., as depositary, will contact ADS holders to arrange the mandatory exchange. No fractional ADSs will be allocated; aggregate fractions will be sold and net proceeds distributed to entitled holders.
-
New CUSIP Identifiers
New ADSs will trade under CUSIP 59564R864, replacing the old CUSIP 59564R872.
Analysis · BDRX · Life Sciences
Biodexa is implementing a 1-for-8 reverse ADS split by changing the ADS ratio from 1 ADS representing 50 ordinary shares to 1 ADS representing 400 ordinary shares. This is a mandatory exchange for ADS holders, with no fractional ADSs allocated. The change is designed to boost the ADS price, which closed at $0.3832 on October 12, 2026, well below the $1.00 Nasdaq minimum bid requirement. The company has been in a prolonged capital-raising cycle with a going concern warning and a cash balance of only £3.23 million as of June 30, 2026, making this reverse split a critical step to maintain Nasdaq listing eligibility.
How filings like this one have moved
In the 30 days to Oct 14, 2026, 29.1% of the 1502 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BDRX was trading at $0.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $360.4K. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.